The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Impact of SARS-CoV-2 mRNA vaccines on PD-L1 expression and immunotherapy outcomes
Adam Grippin, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study investigating the effects of SARS-CoV-2 mRNA vaccines on PD-L1 expression and survival outcomes in patients with stage III/IV non-small cell lung cancer (NSCLC) and metastatic melanoma. Analysis of 3,163 patients revealed that mRNA vaccination within 100 days of biopsy was associated with a improved survival in NSCLC and melanoma, suggesting a synergistic effect of mRNA vaccination and ICI. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
